The In-vitro studies and evaluation of telmisartan marketed tablets
Abstract
Tablets or capsules taken orally remain one of the most effective means of treatment available. The effectiveness of such dosage forms relies on the drug dissolving in the fluids of the gastrointestinal tract prior to absorption into the systemic circulation. The present study reveals the evaluation of four marketed sample of Telmisartan tablets. The main aim of the study is to conduct dissolution test on the tablets to determine the compliance with a given official monograph. Four different marketed samples of Telmisartan were purchased from local market. The Telmisartan tablets were evaluated for the various in-vitro tablet properties such as thickness, hardness, friability, weight variation, drug content, disintegration time and dissolution rate. In-vitro dissolution test is conducted on four different brands of telmisartan tablets to assess their equivalency. All the four marketed samples of Telmisartan have shown good tablet properties and comply with the pharmacopoeial specification. The in- vitro dissolution showed the 80% drug release within one hour from all the four brands which complies with the specification of pharmacopoeia.
DOI
https://doi.org/10.22270/jddt.v9i1.2267References
Patel PKA, et. al., Int J Pharma (IJPSR). 2010; 1(8):282-292.
Bhise S. et al., Int J Pharma (IJPL). 2011; 2(8):970-975.
Vatsal A. P. Optimization and evaluation of a formulation Containing Low Soluble Antihypertensive agent, Marathwada mitra mandal’s college of pharmacy, Off Kalewadi Phata-Pimpri Road, Thergaon Kalewadi, Pune 2012(4); 37-41.
Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ–modulating activity. Hypertension. 2004; 43(5):993-1002.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator–activated receptor-γ activity. Circulation. 2004; 109(17):2054-7.
Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS letters. 2004; 576(3):492-7.
Qi N, Pravenec M, Ho CI, Benson SC, Pershadsingh HA, Sugimoto K, Ogihara T, Kurtz TW. Telmisartan is a dual ARB and PPAR gamma activator that limits weight gain, body fat accumulation, and adipocyte size in rats fed high fat, high carbohydrate diets. Hypertension. 2004; 44(4):506.
Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes care. 2004; 27(4):1015-.
Michel MC, Bohner H, Köster J, Schäfers R, Heemann U. Safety of telmisartan in patients with arterial hypertension. Drug Safety. 2004; 27(5):335-44.
Derosa G, D RAGONESI P, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertension Research. 2004; 27(7):457-64.
Derosa G., Cicero A.F., Bertone G., Piccinni M.N., Fogari E., Ciccarelli L. and Fogari R. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical therapeutics, 2004; 26(8):1228-1236.
Rosano GM, Vitale C, Castiglioni C, Cornoldi A, Fini M, Mercuro G. Comparative effect of telmisartan and losartan on glucose metabolism in hypertensive patients with the metabolic syndrome. InCirculation 2004; 110(17): 606-606).
Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005; 28(3):757-8.
Bloch MJ, Basile JN. Analysis of Recent Papers in Hypertension Jan N. Basile, MD, Senior Editor. The Journal of Clinical Hypertension. 2004; 6(6):342-6.
Doggrell SA. Telmisartan–killing two birds with one stone. Expert opinion on pharmacotherapy. 20041; 5(11):2397-400.
Hisato Takagi , Hirotaka Yamamoto, Kotaro Iwata, Shin-nosuke Goto, Takuya Umemoto and ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, Effects of telmisartan on proteinuria or albuminuria: A metaanalysis of randomized trials, International Journal of Cardiology, 14730; 1-7.
Amr A. Fouad , Iyad Jresat , Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice, Life Sciences, 2011; 89:29-35.
Sameer Goyal , Sachin Arora , Rajan Mittal , Sujata Joshi , Tapas C. Nag c, Ruma Ray , Santosh Kumari , Dharamvir Singh Arya , Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction, European Journal of Pharmacology, 2009; 619:75–84.
Tetsuya Kakumaa, Koro Gotoha, Takayuki Masakia, Emi Itateyamad, Nobuyuki Abee, Hironobu Yoshimatsu, Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome, Obesity Research & Clinical Practice, 2010; 4, e145—e152.
David H.G. Smith, Treatment of Hypertension with an Angiotensin II-Receptor Antagonist Compared with an Angiotensin-Converting Enzyme Inhibitor: A Review of Clinical Studies of Telmisartan and Enalapril, Clinical Therapeutics 2002; 24, NO. IO.
Singh A, Jha KK, Mittal A, Kumar A, A Review on: Telmisartan, Journal of scientific & innovative RESEARCH 2013; 2(1):1-16
EMEA 2005, the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 June 2002; module 8B; 1-18.
Published
Abstract Display: 1099 
PDF Downloads: 949 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.